UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

442O A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma

Annals of oncology, 2024-09, Vol.35, p.S407-S407

2024

Volltextzugriff (PDF)

1453P A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)

Annals of oncology, 2024-09, Vol.35, p.S902-S902

2024

Volltextzugriff (PDF)

47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study

Annals of oncology, 2024-09, Vol.35, p.S230-S230

2024

Volltextzugriff (PDF)

983P Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study

Annals of oncology, 2024-09, Vol.35, p.S671-S671

2024

Volltextzugriff (PDF)

857P Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial

Annals of oncology, 2024-09, Vol.35, p.S618-S619

2024

Volltextzugriff (PDF)

1306P Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study

Annals of oncology, 2024-09, Vol.35, p.S831-S831

2024

Volltextzugriff (PDF)

650P Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S513-S514

2024

Volltextzugriff (PDF)

1649P Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial

Annals of oncology, 2024-09, Vol.35, p.S994-S994

2024

Volltextzugriff (PDF)

103P Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection

Annals of oncology, 2024-09, Vol.35, p.S255-S255

2024

Volltextzugriff (PDF)

261MO Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormone-sensitive prostate cancer receiving rezvilutamide in the CHART trial

Annals of oncology, 2023-11, Vol.34, p.S1575

2023

Volltextzugriff (PDF)

1012P First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression

Annals of oncology, 2023-10, Vol.34, p.S617-S617

2023

Volltextzugriff (PDF)

1467P Combination therapy of envafolimab and suvemcitug with chemotherapy in patients with non-small cell lung cancer (NSCLC): Results from a phase II clinical trial

Annals of oncology, 2023-10, Vol.34, p.S832-S832

2023

Volltextzugriff (PDF)

636P Combination therapy of envafolimab, suvemcitug, and FOLFIRI in patients with metastatic microsatellite stable (MSS) or mismatch-repair proficient (pMMR) colorectal cancer: Results from a phase II clinical trial

Annals of oncology, 2023-10, Vol.34, p.S451-S451

2023

Volltextzugriff (PDF)

611P SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study

Annals of oncology, 2023-10, Vol.34, p.S439-S439

2023

Volltextzugriff (PDF)

971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China

Annals of oncology, 2023-10, Vol.34, p.S603-S603

2023

Volltextzugriff (PDF)

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study

Annals of oncology, 2023-10, Vol.34, p.S480-S480

2023

Volltextzugriff (PDF)

368P A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs

Annals of oncology, 2022-11, Vol.33, p.S1586

2022

Volltextzugriff (PDF)

898P The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

Annals of oncology, 2022-09, Vol.33, p.S958

2022

Volltextzugriff (PDF)

1299P PD-1 blockade plus chemotherapy followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost as induction therapy for patients with borderline resectable and locally advanced pancreatic cancer: A phase II clinical trial

Annals of oncology, 2022-09, Vol.33, p.S1138

2022

Volltextzugriff (PDF)

617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results

Annals of oncology, 2022-09, Vol.33, p.S827

2022

Volltextzugriff (PDF)

880P Phase II trial of the cyclin dependent kinase 4/6 inhibitor SHR6390 in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification

Annals of oncology, 2022-09, Vol.33, p.S950-S951

2022

Volltextzugriff (PDF)

1283P Psychiatric disorders associated with immune checkpoint inhibitors

Annals of oncology, 2022-09, Vol.33, p.S1131

2022

Volltextzugriff (PDF)

1O Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)

Annals of oncology, 2022-04, Vol.33, p.S27

2022

Volltextzugriff (PDF)

949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)

Annals of oncology, 2021-09, Vol.32, p.S826-S826

2021

Volltextzugriff (PDF)

1390P Evaluation of event-free survival as a trial-level surrogate for overall survival for patients with gastric and gastroesophageal junction adenocarcinoma in neoadjuvant/adjuvant settings

Annals of oncology, 2021-09, Vol.32, p.S1052-S1053

2021

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(80)

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

442O A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma

1453P A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)

47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study

983P Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study

857P Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial

1306P Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study

650P Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors

1649P Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial

103P Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection

261MO Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormone-sensitive prostate cancer receiving rezvilutamide in the CHART trial

1012P First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression

1467P Combination therapy of envafolimab and suvemcitug with chemotherapy in patients with non-small cell lung cancer (NSCLC): Results from a phase II clinical trial

636P Combination therapy of envafolimab, suvemcitug, and FOLFIRI in patients with metastatic microsatellite stable (MSS) or mismatch-repair proficient (pMMR) colorectal cancer: Results from a phase II clinical trial

611P SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study

971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study

368P A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs

898P The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

1299P PD-1 blockade plus chemotherapy followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost as induction therapy for patients with borderline resectable and locally advanced pancreatic cancer: A phase II clinical trial

617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results

880P Phase II trial of the cyclin dependent kinase 4/6 inhibitor SHR6390 in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification

1283P Psychiatric disorders associated with immune checkpoint inhibitors

1O Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)

949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)

1390P Evaluation of event-free survival as a trial-level surrogate for overall survival for patients with gastric and gastroesophageal junction adenocarcinoma in neoadjuvant/adjuvant settings

Aktive Filter

Suchergebnisse filtern